Income Statement

v3.8.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Sep. 30, 2017
Sep. 30, 2016
Condensed Consolidated Statements Of Operations        
Revenues, net $ 147,593 $ 167,598 $ 492,364 $ 585,923
Operating expenses:        
Cost of implants and other costs 8,008 37,687 198,023 124,325
Research and development 107,460 159,030
Selling, general and administrative 687,228 626,941 1,972,521 1,571,404
Termination of licensing agreement 132,804
Depreciation and amortization 8,542 20,338 25,396 21,706
Total operating expenses 811,238 684,966 2,354,970 1,850,239
Loss from operations (663,645) (517,368) (1,862,606) (1,264,316)
Other income (expenses):        
Gain on settlement of debt 285,924
Interest expense, net (463,929) (214,192) (10,684,498) (602,551)
Gain (loss) on change in fair value of derivative liability 25,483 (1,877,231) (15,872,510) (2,344,272)
Total other income (expenses) (438,446) (2,091,423) (26,271,084) (2,946,823)
Loss before income taxes (1,102,091) (2,608,791) (28,133,690) (4,211,139)
Income taxes
Net Loss $ (1,102,091) $ (2,608,791) $ (28,133,690) $ (4,211,139)
Net loss per common share, basic and diluted $ (0.00) $ (0.02) $ (0.12) $ (0.03)
Weighted average number of common shares outstanding, basic and diluted 242,538,459 168,832,544 229,106,534 166,397,421

Source